Innovative Therapiekonzepte beim Ovarialkarzinom
作者： K. H. Baumann , U. Wagner
DOI: 10.1007/S00129-006-1890-6
关键词:
摘要: Das Funfjahresgesamtuberleben von Patientinnen mit fortgeschrittenem Ovarialkarzinom liegt bei etwa 30–40% nach operativer und systemischer (Carboplatin Paclitaxel) Therapie. In der Rezidiv- Progressionssituation wird zwischen chemosensitiven chemoresistenten Karzinomerkrankungen unterschieden. Neue Strategien neue Substanzen sind gefordert, die therapeutische Effektivitat beim zu verbessern. dieser Ubersicht werden betrachtet, unter dem Aspekt gezielten Tumortherapie das Spektrum konventionellen Chemotherapeutika durch immunologische oder signaltransduktionsmodifizierende biologische Wirksamkeit erganzen. Zusatzlich Therapierhythmus Dauer erortert.
springer.com
sci-hub.se 参考文章(50)
Alan Husband, Andreas I. Constantinou, Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Research. ,vol. 22, pp. 2581- 2585 ,(2002)
Ayesha B Alvero, Han-Hsuan Fu, Gil Mor, Phenoxodiol, a novel approach for the treatment of ovarian cancer. Current opinion in investigational drugs. ,vol. 7, pp. 542- 548 ,(2006)
Deborah K. Armstrong, John A. Blessing, Katherine Y. Look, Russell Schilder, Evelyn R. Nunez, A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. Investigational New Drugs. ,vol. 21, pp. 373- 377 ,(2003) , 10.1023/A:1025490818450
M. A. Bookman, GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 5002- 5002 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.5002
Christos A. Papadimitriou, Sophia Markaki, John Siapkaras, Georgios Vlachos, Eleni Efstathiou, Irene Grimani, George Hamilos, Markella Zorzou, Meletios-A. Dimopoulos, Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. ,vol. 66, pp. 112- 117 ,(2004) , 10.1159/000077436
R. F. Ozols, Treatment goals in ovarian cancer. International Journal of Gynecological Cancer. ,vol. 15, pp. 3- 11 ,(2005) , 10.1111/J.1525-1438.2005.15351.X
Gautam G Rao, David Scott Miller, Hormonal therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy. ,vol. 6, pp. 43- 47 ,(2006) , 10.1586/14737140.6.1.43
J. Pfisterer, F. Hilpert, A. du Bois, W. Meier, U. Wagner, State-of-the-art first-line treatment of ovarian cancer. Onkologie. ,vol. 26, pp. 446- 450 ,(2003) , 10.1159/000072977
W S Siegel-Lakhai, M Crul, S Zhang, R W Sparidans, D Pluim, A Howes, B Solanki, J H Beijnen, J H M Schellens, Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British Journal of Cancer. ,vol. 93, pp. 1222- 1229 ,(2005) , 10.1038/SJ.BJC.6602850
Jason D. Wright, Andrea Hagemann, Janet S. Rader, Dana Viviano, Randall K. Gibb, Lori Norris, David G. Mutch, Matthew A. Powell, Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma Cancer. ,vol. 107, pp. 83- 89 ,(2006) , 10.1002/CNCR.21969